Navigation Links
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Date:6/4/2009

the ACS and CEA studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials; -- our ability to obtain necessary FDA approvals; -- our ability to successfully commercialize VIA-2291; -- our ability to identify potential clinical candidates from the compounds in DGAT1 and move them into preclinical development; -- our ability to obtain and protect our intellectual property related to our product candidates; -- our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche; -- our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291; -- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates; -- general economic and business conditions; and -- the other risks described under Item IA "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
11. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences ... Decipher Prostate Cancer Classifier, a genomic test for prostate ... node-negative, high-risk men managed by radical prostatectomy without adjuvant ... prostatectomy is relatively uncommon, using tumor genomics to identify ... metastatic disease is an important advance. The study has ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... most Americans take the safety of their drinking water ... within minutes, says Prof. Abraham Katzir of Tel Aviv ... the threat of contamination due to industrial spillage, natural ... system to monitor the safety of a building or ...
... with inoperable lung cancer is able to receive stereotactic ... told Donald Bickford, 71, that due to the weakened ... option for removing his lung tumor. To treat the ... here, prescribed a type of non-invasive radiosurgery using the ...
... Cellular Bioengineering, Inc. (CBI) announces it is developing a ... medicine and other consumables, but can also be used ... parts, great works of art, currency, electronic components, high ... the Multimedia News Release go to: ...
Cached Biology Technology:Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 2Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology 3Photos: Breakthrough Technology Enables Edible TruTag(TM) to Prevent Counterfeit Medicine 2Photos: Breakthrough Technology Enables Edible TruTag(TM) to Prevent Counterfeit Medicine 3
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... the Proceedings of the National Academy of Sciences ... shape the way people interact may be just as ... themselves. "Tipping points," qualitative changes in an ecosystem ... difficult and costly to reverse increasingly concern environmental scientists. ...
... sensors designed to measure saltiness and temperature across the world,s ... an ambitious expedition. A four-man team of officers from ... from Australia to Mauritius on Sunday (17 April). They plan ... Trust and the Mark Evison Foundation when they row in ...
... in cancer patients to predict clinical outcome has been ... but now researchers at the Kimmel Cancer Center at ... cancer cell metabolism with poor clinical outcome. This approach ... human cancer cell. The researchers demonstrate that ...
Cached Biology News:Human rules may determine environmental 'tipping points' 2Human rules may determine environmental 'tipping points' 3Jefferson researchers unlock key to personalized cancer medicine using tumor metabolism 2Jefferson researchers unlock key to personalized cancer medicine using tumor metabolism 3
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Request Info...
... Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT) ... DNA, RNA or RNA:DNA hybrids (1). It ... efficient than RNA primers) as well as ... intrinsic RNase H activity. Both nonionic detergents ...
Biology Products: